TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FOSAMAX PLUS D

ALENDRONATE SODIUM
Approved 2005-04-07
2
Indications
--
Phase 3 Trials
20
Years on Market

Details

Status
Prescription
First Approved
2005-04-07
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ALENDRONATE SODIUM , CHOLECALCIFEROL

FOSAMAX PLUS D Approval History

Loading approval history...

What FOSAMAX PLUS D Treats

2 indications

FOSAMAX PLUS D is approved for 2 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Osteoporosis
  • Vitamin D Deficiency
Source: FDA Label

Drugs Similar to FOSAMAX PLUS D

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACTIVELLA
ESTRADIOL
1 shared
Novo Nordisk
Shared indications:
Osteoporosis
ATELVIA
RISEDRONATE SODIUM
1 shared
APIL
Shared indications:
Osteoporosis
BILDYOS
DENOSUMAB-NXXP
1 shared
SHANGHAI HENLIUS BIOTECH
Shared indications:
Osteoporosis
BINOSTO
ALENDRONATE SODIUM
1 shared
RADIUS
Shared indications:
Osteoporosis
BONCRESA
DENOSUMAB-MOBZ
1 shared
AMNEAL PHARMS LLC
Shared indications:
Osteoporosis
BONSITY
TERIPARATIDE
1 shared
ALVOGEN
Shared indications:
Osteoporosis
BOSAYA
DENOSUMAB-KYQQ
1 shared
BIOCON BIOLOGICS INC
Shared indications:
Osteoporosis
CLIMARA
ESTRADIOL
1 shared
Bayer
Shared indications:
Osteoporosis
CLIMARA PRO
ESTRADIOL
1 shared
BERLEX LABS
Shared indications:
Osteoporosis
CONEXXENCE
DENOSUMAB-BNHT
1 shared
Fresenius Kabi
Shared indications:
Osteoporosis
CONJUGATED ESTROGENS
ESTROGENS, CONJUGATED
1 shared
NOVAST LABS
Shared indications:
Osteoporosis
DUAVEE
BAZEDOXIFENE ACETATE
1 shared
Pfizer
Shared indications:
Osteoporosis
ENOBY
DENOSUMAB-QBDE
1 shared
Hikma
Shared indications:
Osteoporosis
ESTRADIOL
ESTRADIOL
1 shared
Viatris
Shared indications:
Osteoporosis
ESTRADIOL AND NORETHINDRONE ACETATE
ESTRADIOL
1 shared
Teva
Shared indications:
Osteoporosis
EVENITY
ROMOSOZUMAB-AQQG
1 shared
Amgen
Shared indications:
Osteoporosis
EVISTA
RALOXIFENE HYDROCHLORIDE
1 shared
Eli Lilly
Shared indications:
Osteoporosis
FORTEO
TERIPARATIDE
1 shared
Eli Lilly
Shared indications:
Osteoporosis
FYAVOLV
ETHINYL ESTRADIOL
1 shared
Lupin
Shared indications:
Osteoporosis
IBANDRONATE SODIUM
IBANDRONATE SODIUM
1 shared
Apotex
Shared indications:
Osteoporosis
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FOSAMAX PLUS D FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Limitations of use : FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX ยฎ PLUS D is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, FOSAMAX...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.